Literature DB >> 26955982

Psychoeducation Improves Compliance and Outcome in Schizophrenia Without an Increase of Adverse Side Effects: A 7-Year Follow-up of the Munich PIP-Study.

Josef Bäuml1, Gabriele Pitschel-Walz2, Anja Volz2, Sandra Lüscher2, Michael Rentrop2, Werner Kissling2, Thomas Jahn2.   

Abstract

Psychoeducation improves adherence and motivates patients to accept a maintenance therapy as recommended by the guidelines. This would mean a daily consumption of at least 300 chlorpromazine (CPZ) units in the long run and should lead to an increase of the antipsychotic dosage in comparison to patients with treatment as usual (TAU). This raises 2 important questions: whether more side effects are provoked and do the patients have a corresponding benefit with a better outcome. A total of 41 patients with a diagnosis of schizophrenic or schizoaffective disorder were randomized at study entry, either to bifocal psychoeducation (21), or to standard treatment (20). They were compared concerning compliance, type of medication, dosage (CPZ equivalents), motor side effects and number of days in hospital. The average daily antipsychotic medication 2 and 7 years after index discharge was 365 and 354 CPZ-units respectively in the intervention group (IG), but 247 and 279, respectively in the control group (CG). The extent of motor side effects was slightly smaller in the IG, but they showed a small and statistically not significant increase in the rate of tardive dyskinesia (TD) after 7 years. At the 7-year follow-up the patients in the IG had spent 74.7 days in hospital compared to 243.4 days for the patients in the CG (P < .05). The course of illness was significantly better in the IG without increasing motor side-effects. Therefore, psychoeducation should be integrated more systematically into the routine treatment. These data are part of a previous study, published 2007, with a sample size of 48 patients. Seven patients-3 of the IG and 4 of the CG-could not be included, because they were not able to complete the very complex "Computer-based kinematic analysis of motor performance." In this article all conclusions are referred to the new sample size, therefore some results are slightly different in comparison to the previous data.
© The Author 2016. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  EPMS; psychoeducation; rehospitalization; schizophrenia; side effects; tardive dyskinesia

Mesh:

Substances:

Year:  2016        PMID: 26955982      PMCID: PMC4960435          DOI: 10.1093/schbul/sbw008

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  43 in total

Review 1.  Pharmacologic treatment of schizophrenia.

Authors:  J M Kane
Journal:  Biol Psychiatry       Date:  1999-11-15       Impact factor: 13.382

2.  The appropriateness of routine medication treatment for schizophrenia.

Authors:  Alexander S Young; Noosha Niv; Amy N Cohen; Christopher Kessler; Kirk McNagny
Journal:  Schizophr Bull       Date:  2008-11-07       Impact factor: 9.306

3.  Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment.

Authors:  N R Schooler; S J Keith; J B Severe; S M Matthews; A S Bellack; I D Glick; W A Hargreaves; J M Kane; P T Ninan; A Frances; M Jacobs; J A Lieberman; R Mance; G M Simpson; M G Woerner
Journal:  Arch Gen Psychiatry       Date:  1997-05

Review 4.  Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery?

Authors:  Martin Harrow; Thomas H Jobe
Journal:  Schizophr Bull       Date:  2013-03-19       Impact factor: 9.306

5.  Psychoeducation and compliance in the treatment of schizophrenia: results of the Munich Psychosis Information Project Study.

Authors:  Gabriele Pitschel-Walz; Josef Bäuml; Wolfram Bender; Rolf R Engel; Michael Wagner; Werner Kissling
Journal:  J Clin Psychiatry       Date:  2006-03       Impact factor: 4.384

6.  Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses.

Authors:  Maximilian Huhn; Magdolna Tardy; Loukia Maria Spineli; Werner Kissling; Hans Förstl; Gabriele Pitschel-Walz; Claudia Leucht; Myrto Samara; Markus Dold; John M Davis; Stefan Leucht
Journal:  JAMA Psychiatry       Date:  2014-06       Impact factor: 21.596

7.  Severe and uncommon involuntary movement disorders due to psychotropic drugs.

Authors:  S Stübner; E Rustenbeck; R Grohmann; G Wagner; R Engel; G Neundörfer; H-J Möller; H Hippius; E Rüther
Journal:  Pharmacopsychiatry       Date:  2004-03       Impact factor: 5.788

8.  Non-adherence to antipsychotic medication regimens: associations with resource use and costs.

Authors:  Martin Knapp; Derek King; Klaus Pugner; Pablo Lapuerta
Journal:  Br J Psychiatry       Date:  2004-06       Impact factor: 9.319

Review 9.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

Review 10.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

View more
  8 in total

Review 1.  Can Smartphone Apps Assist People with Serious Mental Illness in Taking Medications as Prescribed?

Authors:  Cynthia L Bianco; Amanda L Myers; Stephen Smagula; Karen L Fortuna
Journal:  Sleep Med Clin       Date:  2020-12-07

2.  Special Supplement Introduction: The Fourth Kraepelin Symposium-Cognitive Dysfunction in Schizophrenia: Origins and Innovative Treatment.

Authors:  Annette Schaub; Peter Falkai
Journal:  Schizophr Bull       Date:  2016-07       Impact factor: 9.306

3.  What side effects are problematic for patients prescribed antipsychotic medication? The Maudsley Side Effects (MSE) measure for antipsychotic medication.

Authors:  T Wykes; J Evans; C Paton; T R E Barnes; D Taylor; R Bentall; B Dalton; T Ruffell; D Rose; S Vitoratou
Journal:  Psychol Med       Date:  2017-04-19       Impact factor: 7.723

4.  Treatment Compliance in the Long-Term Paranoid Schizophrenia Telemedicine Study.

Authors:  Marek Krzystanek; Krzysztof Krysta; Katarzyna Skałacka
Journal:  J Technol Behav Sci       Date:  2017-05-18

5.  Pharmacological Treatment for Long-Term Patients with Schizophrenia and Its Effects on Sleep in Daily Clinical Practice: A Pilot Study.

Authors:  Peggy Bosch; Sabina Lim; Heike Staudte; Sujung Yeo; Sook-Hyun Lee; Pia Barisch; Benoît Perriard; Maurits Van den Noort
Journal:  Medicines (Basel)       Date:  2018-05-12

6.  An intensive multimodal group programme for patients with psychotic disorders at risk of rehospitalization: a controlled intervention study.

Authors:  Mark H de Jong; André I Wierdsma; Arthur R Van Gool; Cornelis L Mulder
Journal:  BMC Psychiatry       Date:  2019-08-05       Impact factor: 3.630

7.  A 2-year longitudinal study of neuropsychological functioning, psychosocial adjustment and rehospitalisation in schizophrenia and major depression.

Authors:  Schaub Annette; Goerigk Stephan; Kim T Mueser; Hautzinger Martin; Roth Elisabeth; Goldmann Ulrich; Charypar Marketa; Engel Rolf; Möller Hans-Jürgen; Falkai Peter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-04-03       Impact factor: 5.270

8.  Mental Health Nurses' Tacit Knowledge of Strategies for Improving Medication Adherence for Schizophrenia: A Qualitative Study.

Authors:  Yao-Yu Lin; Wen-Jiuan Yen; Wen-Li Hou; Wei-Chou Liao; Mei-Ling Lin
Journal:  Healthcare (Basel)       Date:  2022-03-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.